Login / Signup
Nathalie Kertesz
ORCID
Publication Activity (10 Years)
Years Active: 2022-2024
Publications (10 Years): 8
Top Topics
Replacement Therapy
Open Label
Prognostic Factors
Monoclonal Antibody
Top Venues
Neurology
BMC pediatrics
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Thomas O Crawford
,
Basil T Darras
,
John W Day
,
Sally Dunaway Young
,
Tina Duong
,
Leslie L Nelson
,
Doreen Barrett
,
Guochen Song
,
Sanela Bilic
,
Shaun M Cote
,
Mara Sadanowicz
,
Ryan Iarrobino
,
Tiina J Xu
,
Janet O'Neil
,
José Rossello
,
Amy Place
,
Nathalie Kertesz
,
George Nomikos
,
Yung Chyung
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Neurology
102 (5) (2024)
Thomas O Crawford
,
Basil T Darras
,
John W Day
,
Sally Dunaway Young
,
Tina Duong
,
Leslie L Nelson
,
Doreen Barrett
,
Guochen Song
,
Sanela Bilic
,
Shaun M Cote
,
Mara Sadanowicz
,
Ryan Iarrobino
,
Tiina J Xu
,
Janet O'Neil
,
José Rossello
,
Amy Place
,
Nathalie Kertesz
,
George Nomikos
,
Yung Chyung
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Neurology
102 (5) (2024)
Thomas O Crawford
,
Basil T Darras
,
John W Day
,
Sally Dunaway Young
,
Tina Duong
,
Leslie L Nelson
,
Doreen Barrett
,
Guochen Song
,
Sanela Bilic
,
Shaun M Cote
,
Mara Sadanowicz
,
Ryan Iarrobino
,
Tiina J Xu
,
Janet O'Neil
,
José Rossello
,
Amy Place
,
Nathalie Kertesz
,
George Nomikos
,
Yung Chyung
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Neurology
102 (5) (2024)
Thomas O Crawford
,
Basil T Darras
,
John W Day
,
Sally Dunaway Young
,
Tina Duong
,
Leslie L Nelson
,
Doreen Barrett
,
Guochen Song
,
Sanela Bilic
,
Shaun M Cote
,
Mara Sadanowicz
,
Ryan Iarrobino
,
Tiina J Xu
,
Janet O'Neil
,
José Rossello
,
Amy Place
,
Nathalie Kertesz
,
George Nomikos
,
Yung Chyung
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Neurology
102 (5) (2024)
Thomas O Crawford
,
Basil T Darras
,
John W Day
,
Sally Dunaway Young
,
Tina Duong
,
Leslie L Nelson
,
Doreen Barrett
,
Guochen Song
,
Sanela Bilic
,
Shaun M Cote
,
Mara Sadanowicz
,
Ryan Iarrobino
,
Tiina J Xu
,
Janet O'Neil
,
José Rossello
,
Amy Place
,
Nathalie Kertesz
,
George Nomikos
,
Yung Chyung
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Neurology
102 (5) (2024)
Thomas O Crawford
,
Basil T Darras
,
John W Day
,
Sally Dunaway Young
,
Tina Duong
,
Leslie L Nelson
,
Doreen Barrett
,
Guochen Song
,
Sanela Bilic
,
Shaun M Cote
,
Mara Sadanowicz
,
Ryan Iarrobino
,
Tiina J Xu
,
Janet O'Neil
,
José Rossello
,
Amy Place
,
Nathalie Kertesz
,
George Nomikos
,
Yung Chyung
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Neurology
102 (5) (2024)
Thomas O Crawford
,
Basil T Darras
,
John W Day
,
Sally Dunaway Young
,
Tina Duong
,
Leslie L Nelson
,
Doreen Barrett
,
Guochen Song
,
Sanela Bilic
,
Shaun M Cote
,
Mara Sadanowicz
,
Ryan Iarrobino
,
Tiina J Xu
,
Janet O'Neil
,
José Rossello
,
Amy Place
,
Nathalie Kertesz
,
George Nomikos
,
Yung Chyung
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Neurology
102 (5) (2024)
John W Day
,
Kelly Howell
,
Amy Place
,
Kimberly Long
,
Jose Rossello
,
Nathalie Kertesz
,
George Nomikos
Advances and limitations for the treatment of spinal muscular atrophy.
BMC pediatrics
22 (1) (2022)